medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2016, Number 5

<< Back Next >>

Acta Pediatr Mex 2016; 37 (5)

Benefits of L-carnitine supplementation in pediatric hemodialysis patients: Cases report

Martínez-Morales JA, Raya-Jiménez P, Monroy-Torres R, Daza-Benítez L

Language: Spanish
References: 17
Page: 260-270
PDF size: 594.58 Kb.


ABSTRACT

Introduction: Most pediatric patients with chronic renal failure develop mal nutrition and anemia. To treat anemia, erythropoietin (EPO) is administered as a treatment of choice, but does not recover the nutritional status of the patient, so that L-carnitine, is presented as an alternative that improves the nutritional status, while It decreases the frequency of anemia.
Objetive: To improve the biochemical and anthropometric parameters, after supplementation with L-carnitine in pediatric patients.
Material and Method: A longitudinal study, case series in 25 participants, both sexes, aged 3-16 years old, with chronic renal failure and hemodialysis was performed. They were provided L-carnitine i.v. (50 mg / kg / session), 30 minutes before finishing hemodialysis sessions for three months (36 sessions). Before and after the maneuver some biochemical parameters (hemoglobin, albumin, cholesterol, triglycerides, creatinine) and anthropometric were compared. a comparison with T Student and proportions (cases improved after switching and absolute risk reduction) was performed mainly.
Results: The average age of cases was 12.4 years (range 3-16 years). When comparing cases with T student, a significant improvement with supplementation for dry weight (p = 0.004), body mass index (p = 0.04), albumin (p = 0.02) and cholesterol (p = 0.003) was obtained. With the calculation proportions of cases improved with the maneuver, reducing the risk attributable observed in a range from 12 to 68% of all of the variables of interest (hemoglobin, albumin, cholesterol, triglycerides, dry weight and BMI).
Conclusion: Supplementation connote-carnitine I.V. 50 mg / kg / session, 30 minutes before the end of each hemodialysis session for three months, allowed an improvement in the percentage of case studies for dry weight, BMI, albumin, hemoglobin, cholesterol and triglycerides, a reduction attributable risk of 12 to 68% of cases.


REFERENCES

  1. Troche A, Ávalos D, Ferreira S, Zarza de Bolaños M .Características epidemiológicas de la insuficiencia renal crónica (IRC) en Pediatría. Rev Parag Pediatr. 2005(32):122-39.

  2. Martínez GT, García JA. Desnutrición energético-proteínica. En: Casanueva E, Kaufere M, Pérez AB, Arroyo P. Nutriología Médica. 3ª edición. México: Médica Panamericana; 2008. p. 263-295.

  3. Susan M, Geary DF. Anemia in children with chronic kidney disease. Pediatr Nephrol 2008;23(2):209- 219.

  4. Caló LA, Vertolli U, Davis PA, Savica V. L carnitine in hemodialysis patients. Hemodial Int. 2012;16(3):428-34.

  5. Fischbach M, Edefonti A, Schroder C, Watson A and The European Pediatric Dialysis Working Group. Hemodialysis in children: general practical guidelines. Pediatr Nephrol. 2005;20(8):1054-1066.

  6. National Center for Toxicological Research. Annual. Report. http://www.fda.gov/downloads/AboutFDA/CentersOffices/ OC/OfficeofScientificandMedicalPrograms/NCTR/ ResearchAccomplishmentsPlans/UCM257438.pdf

  7. COFEPRIS. Relación de certificados de libre venta emitidos durante el 2do semestre del 2011. http://www.encuentra. gob.mx/resultsAPF.html?q=levocarnitina&client=cofepris

  8. Hurot JM, Cucherat M, Haugh M, Fouque D. Effects of L-Carnitine Supplementation in Maintenance Hemodialysis Patients: A Systematic Review. J Am Soc Nephrol. 2002;13(3):708-714.

  9. Matsura M, Hatakeyama S, koni I, Mabuchi H, Muramoto H. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis Patients. J Nephrol. 2008;72(4):5.

  10. Kathleen L and EscottS. Terapia nutricional médica en trastornos renales. In: Wilkens K and Juneja V. (eds.) Krause Dietoterapia. 12th ed. Barcelona, España: MASSON; 2009:921-959.

  11. Sabry AA. The role of oral L-Carnitine therapy in chronic hemodialysis patients. Saudi J kidney Dis transpl. 2010;21(3):454-459.

  12. Ávila H, Caraveo VE, Valcez R, Tejero E. Evaluación del estado de nutrición. En: Casanueva E, Kaufere M, Pérez AB, Arroyo P. Nutriología Médica. 3ª edición. México: Médica Panamericana; 2008. p. 747-783.

  13. Aoun B, Berard E, Vitkevic R, Dehée A, Bensman A, Ulinski T. L-carnitine supplementation and EPO requirement in children on chronic hemodialysis. Pediatr Nephrol 2010;25:557-560.

  14. Lilien MR, Duran M, Quak JM, Frankhuisen JJ, Schröder CH. Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 2000;15:17-20.

  15. Nikolaos S, George A, Telemachos T, Maria S, Yannis M, Konstantinos M. Effect of L-carnitine supplementation on red blood cell deformability in hemodialysis patients. Ren Fail 2000;22(1):73-80.

  16. Blumenkrantz MJ, Kopple JD, Gutman RA, Chan YK, Barbour GL, Roberts C y cols. Methods for assessing nutritional status of patients with renal failure. Am J Clin Nutr 1980;33(7):1567-1585.

  17. Günes B, Yalcin SS, kalkanoglu HS, Onol S, Dursun A, Coşkun T. The effect of oral L-carnitine supplementation on the lipid profiles of hyperlipidaemic in children. Acta Paediatrica 2005;94(6):711-716.




2020     |     www.medigraphic.com